Development and Market Objectives

We aim to develop a first-in-class disease-modifying medicine for Type 1 Diabetes Mellitus (T1DM) patients with minimized side effects.

Unmet Medical Need & Target Patients

T1DM, juvenile-onset diabetes, is an autoimmune disease characterized by T cell-mediated destruction of pancreatic β cells, resulting in insulin deficiency and hyperglycemia. The incidence of T1DM has been growing rapidly, with an estimated 2 million T1DM patients worldwide and approximately 70 thousand in children under the age of 14 diagnosed annually. Although, injectable insulin therapy is an available life-saving first-line treatment, a significant unmet need exists for a highly reliable treatment option that can address the discomfort of daily subcutaneous injections and the side-effects of hypoglycemia.

Current Progress

We are currently developing human T cell-specific monoclonal antibodies (mAbs) and validating the candidates through in vitro/in vivo efficacy and reliability assessments. For further pre-clinical tests on selected mAbs, we have generated a transgenic T1DM mouse model, which express human TCR components. Evaluation of the selected mAbs is underway using the humanized transgenic T1DM mouse model.

Intellectual Property

Two domestic and PCT applications filed, respectively.

Competitive Advantages

In contrast to insulin-therapy which only alleviates symptoms, our goal is to develop a disease-modifying therapy with long-term efficacy (> 6 months). Our humanized transgenic T1DM mouse model facilitates developing superior candidates. We shall develop innovative biological immuno-modulators free from non-specific activation or side effects.

Disease Target

Diabetes

Project duration

Jan 1, 2014 ~ Feb 29, 2016

Organization

Medytox Inc.

Phase of Development

Lead

Contact

• Organization: Medytox Inc.
• Website: http://www.medytox.com/
• Contact Person: Sun Taek Kim
• E-mail: stkim@medytox.com
• Phone No.: +82-70-8666-7689

Related Projects